期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 24, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/ijms24043727
关键词
hypomethylating agents; acute myeloid leukemia; PD-1; CD47
Hypomethylating agents (HMAs) have been used for a long time in the treatment of hematologic neoplasms. Recent studies have shown their potential in combination with targeted agents and immune-checkpoint inhibitors. This review discusses the immuno-oncological backgrounds, therapeutic mechanisms, and current clinical trials of HMAs and/or venetoclax-based combination therapies in leukemia.
Hypomethylating agents (HMAs) have been used for decades in the treatment of hematologic neoplasms, and now, have gathered attention again in terms of their combination with potent molecular-targeted agents such as a BCL-6 inhibitor venetoclax and an IDH1 inhibitor ivosidenib, as well as a novel immune-checkpoint inhibitor (anit-CD47 antibody) megrolimab. Several studies have shown that leukemic cells have a distinct immunological microenvironment, which is at least partially due to genetic alterations such as the TP53 mutation and epigenetic dysregulation. HMAs possibly improve intrinsic anti-leukemic immunity and sensitivity to immune therapies such as PD-1/PD-L1 inhibitors and anti-CD47 agents. This review describes the immuno-oncological backgrounds of the leukemic microenvironment and the therapeutic mechanisms of HMAs, as well as current clinical trials of HMAs and/or venetoclax-based combination therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据